CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors
Journal of Clinical Investigation · 01.08.2025 · 135 (15)
DOI: 10.1172/jci189920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 06.06.2025. Verfasst von Tianchen Xiong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology & Hematopoietic Cell Transplantation and. Hauptthemen laut MEDLINE: Receptors, Virus, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, City of Hope National Medical Center.
Abstract (Originalsprache)
CAR-T cells are a powerful yet expensive tool in cancer immunotherapy. Although their use in targeting hematological malignancies is well established, using a single CAR-T cell therapy to treat both hematological and solid tumors, which can reduce cost, remains largely unexplored. In this study, we identified CD155, an adhesion molecule that is upregulated during tumor progression, as a target for CAR-T cell therapy in both leukemia and solid tumors. We engineered CAR-T cells using human and mouse anti–CD155 antibodies generated from a Berkeley Lights’ Beacon platform. These CAR-T cells demonstrated potent antitumor activity, significantly reducing tumor burden in preclinical models of acute myeloid leukemia, non–small cell lung cancer, and pancreatic cancer. To reduce potential allogeneic rejection, we generated CAR-T cells using humanized anti–CD155 antibody sequences that retained efficacy. Additionally, murine CAR-T cells targeting mouse CD155 exhibited limited toxic side effects in immunocompetent mice, highlighting the favorable safety profile of this therapy. These findings suggest that CD155 can be targeted by CD155 CAR-T cells safely and effectively, representing an innovative cellular therapeutic strategy that has the potential to expand its scope across both AML and multiple solid tumors, thereby lowering the cost of cellular immunotherapy, especially as allogenic, universal, and off-the-shelf CAR-T cell therapies advance to the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology & Hematopoietic Cell Transplantation and.
- Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, California, USA.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
- Chongqing International Institute for Immunology, Chongqing, China.
- Department of Computational and Quantitative Medicine and.
- Gehr Family Center for Leukemia Research, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, California, USA.
Förderung
- NCI NIH HHS
- City of Hope National Medical Center
Zitieren
APA
Xiong, T., Wang, G., Yu, P., Li, Z., Li, D., Zhang, J., Lu, S., Yang, R., Lian, X., Mi, J., Ma, R., Li, Z., Marcucci, G., Zhao, T., Caligiuri, M. A., & Yu, J. (2025). CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. Journal of Clinical Investigation, 135(15). https://doi.org/10.1172/jci189920
Vancouver
Xiong T, Wang G, Yu P, Li Z, Li D, Zhang J, et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. Journal of Clinical Investigation. 2025;135(15). doi:10.1172/jci189920
BibTeX
@article{Xiong2025,
author = {Xiong, Tianchen and Wang, Ge and Yu, Peng and Li, Zhenlong and Li, Debao and Zhang, Jianying and Lu, Song and Yang, Ruiqi and Lian, Xiaolong and Mi, Jianhong and Ma, Rui and Li, Zhiyao and Marcucci, Guido and Zhao, Tingting and Caligiuri, Michael A and Yu, Jianhua},
title = {CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {15},
doi = {10.1172/jci189920}
}
EUVIMED